TABLE 1

Proportional prevalence of anti-tuberculosis (TB) drug-resistance by treatment history in rifampicin-resistant (RR)-/multidrug-resistant (MDR)-TB cases in the European Union and European Economic Area countries 2010–2014.

Kanamycin or amikacinMoxifloxacin or ofloxacinEthambutolAll drugs
Notified RR-/MDR-TB casesResistant/tested% (95% CI)Resistant/tested% (95% CI)Resistant/tested% (95% CI)Susceptible/tested% (95% CI)
All cases75501487/474731.3 (30.0–32.6)1094/426125.6 (24.4–27.0)3054/471664.8 (63.4–66.1)1302/419231.1 (29.7–32.5)
Treatment history
 New cases3103519/206825.1 (23.2–27.0)345/198417.4 (15.7–19.1)1237/206459.9 (57.8–62.0)681/196534.7 (32.6–36.8)
 Previously treated4119928/250937.0 (35.1–38.9)711/210633.8 (31.7–35.8)1722/248369.4 (67.5–71.2)560/206327.1 (25.2–29.1)
 Unknown32840/17023.5 (17.15–29.9)38/17122.2 (16.0–28.45)95/16956.2 (48.7–63.7)61/16437.2 (29.8–44.6)
  • Data are presented as n, unless otherwise stated. Data from Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, Germany, Greece, Hungary, Iceland, Ireland, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Sweden and the United Kingdom.